Current Oncology Reports

, Volume 5, Issue 2, pp 87–88

Pegylated interferon alfa-2b as treatment of solid tumors

  • Authors
  • Ronald M. Bukowski
Clinical Trials Report

DOI: 10.1007/s11912-003-0094-7

Cite this article as:
Bukowski, R.M. Curr Oncol Rep (2003) 5: 87. doi:10.1007/s11912-003-0094-7

Conclusions

PEG-IFN á-2b is active in patients with metastatic RCC and melanoma and is tolerated well at doses up to 6.0 μg/kg/wk. This trial provides a rationale for further studies using this pegylated cytokine alone or in combination with such agents as interleukin (IL)-2.

Copyright information

© Current Science Inc. 2003